Background: Accurate methods for cross-sectional incidence estimation are needed for HIV surveillance and HIV prevention research. Third generation HIV screening tests, such as Genetic Systems (GS) HIV 1 /2 +O ELISA, have been modified for use as incidence assays, but are not available in many countries and may be replaced with more sensitive 4th generation HIV assays. We developed an HIV avidity assay based on the 4th generation GS HIV Combo Ag/Ab EIA (BioRad Combo assay) and evaluated its performance.
Methods: The BioRad Combo assay was modified by diluting samples 1:10 and incubating them for 30 minutes at 4°C, with and without 0.025 M diethylamine (DEA). The avidity index (AI) was calculated as the optical density ratio of the DEA-treated to the untreated well. We analyzed 1,541 samples from the United States that were collected in the HIV Network for Prevention Trials (HIVNET) 001/001.1 study, the AIDS Linked to the Intravenous Experience Study (ALIVE) cohort, the Johns Hopkins Hospital Clinical Cohort (JHHCC), and the Johns Hopkins Elite Suppressor cohort (ES). Assay performance was assessed using the modified BioRad Combo assay alone, or with a viral load (VL) assay (classifying samples with a VL <400 copies/mL as non-recent). HIVNET 001 samples were used to estimate the mean duration of recent infection (MDRI) using a time window of 2 years for AI cut-offs of 20-90%. The false recent rate (FRR, fraction of samples misclassified as recent), was calculated for the ALIVE and JHHCC samples. Assay reproducibility was also evaluated.
Results: Table 1 shows the performance characteristics of the modified BioRad Combo assay at different AI cutoffs alone and in combination with VL. Neither of these approaches provided a MDRI >100 days with a FRR <1%. All samples from elite suppressors had an AI >80%. AI values were significantly correlated between two technologists (r=0.93; p<0.01).
Conclusions: The performance characteristics of this assay suggest that it may be useful as one component of a multi-assay algorithm (MAA) for HIV incidence estimation. When combined with a VL exclusion the FRR was halved but MDRI estimates were reduced by approximately 10%. This may provide a useful tool for HIV incidence estimation in the future, if 3rd generation HIV screening tests are replaced with 4th generation tests for HIV diagnosis. Further research is needed to evaluate the modified BioRad Combo assay in combination with other assays to accurately estimate HIV incidence based on 4th generation HIV tests.